ProShare Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-4,808
| Closed | -$224K | – | 1829 |
|
|
2022
Q4 | $224K | Buy |
4,808
+374
| +8% | +$17.1K | ﹤0.01% | 1417 |
|
|
2022
Q3 | $230K | Buy |
4,434
+92
| +2% | +$5.38K | ﹤0.01% | 1312 |
|
|
2022
Q2 | $206K | Sell |
4,342
-2,091
| -33% | -$113K | ﹤0.01% | 1455 |
|
|
2022
Q1 | $458K | Sell |
6,433
-1,200
| -16% | -$78.1K | ﹤0.01% | 1336 |
|
|
2021
Q4 | $570K | Buy |
7,633
+384
| +5% | +$30.1K | ﹤0.01% | 1355 |
|
|
2021
Q3 | $412K | Sell |
7,249
-1,865
| -20% | -$92.2K | ﹤0.01% | 1327 |
|
|
2021
Q2 | $401K | Buy |
9,114
+648
| +8% | +$31.7K | ﹤0.01% | 1694 |
|
|
2021
Q1 | $418K | Buy |
8,466
+804
| +10% | +$40.1K | ﹤0.01% | 1565 |
|
|
2020
Q4 | $323K | Buy |
7,662
+1,768
| +30% | +$77.8K | ﹤0.01% | 1560 |
|
|
2020
Q3 | $270K | Sell |
5,894
-161
| -3% | -$7.8K | ﹤0.01% | 1243 |
|
|
2020
Q2 | $304K | Buy |
6,055
+1,967
| +48% | +$102K | ﹤0.01% | 1222 |
|
|
2020
Q1 | $210K | Sell |
4,088
-2,943
| -42% | -$157K | ﹤0.01% | 995 |
|
|
2019
Q4 | $434K | Sell |
7,031
-655
| -9% | -$40.6K | ﹤0.01% | 1137 |
|
|
2019
Q3 | $462K | Sell |
7,686
-288
| -4% | -$21.4K | ﹤0.01% | 1007 |
|
|
2019
Q2 | $673K | Sell |
7,974
-905
| -10% | -$81.4K | ﹤0.01% | 903 |
|
|
2019
Q1 | $848K | Buy |
8,879
+88
| +1% | +$7.89K | 0.01% | 834 |
|
|
2018
Q4 | $623K | Sell |
8,791
-1,560
| -15% | -$120K | ﹤0.01% | 871 |
|
|
2018
Q3 | $885K | Sell |
10,351
-421
| -4% | -$42.2K | 0.01% | 870 |
|
|
2018
Q2 | $1.25M | Sell |
10,772
-514
| -5% | -$51.3K | 0.01% | 758 |
|
|
2018
Q1 | $913K | Sell |
11,286
-1,737
| -13% | -$134K | 0.01% | 864 |
|
|
2017
Q4 | $764K | Buy |
13,023
+925
| +8% | +$46.3K | 0.01% | 944 |
|
|
2017
Q3 | $566K | Buy |
12,098
+723
| +6% | +$29.1K | 0.01% | 909 |
|
|
2017
Q2 | $409K | Sell |
11,375
-909
| -7% | -$29.1K | ﹤0.01% | 1026 |
|
|
2017
Q1 | $378K | Sell |
12,284
-3,109
| -20% | -$96.8K | ﹤0.01% | 1124 |
|
|
2016
Q4 | $516K | Buy |
15,393
+1,573
| +11% | +$45.1K | 0.01% | 1057 |
|
|
2016
Q3 | $368K | Sell |
13,820
-2,498
| -15% | -$58K | 0.01% | 1071 |
|
|
2016
Q2 | $360K | Buy |
16,318
+48
| +0.3% | +$1.26K | ﹤0.01% | 1116 |
|
|
2016
Q1 | $478K | Sell |
16,270
-1,433
| -8% | -$39.9K | 0.01% | 1018 |
|
|
2015
Q4 | $585K | Buy |
17,703
+1,659
| +10% | +$54.1K | 0.01% | 969 |
|
|
2015
Q3 | $580K | Sell |
16,044
-911
| -5% | -$39.1K | 0.01% | 885 |
|
|
2015
Q2 | $763K | Sell |
16,955
-94
| -0.6% | -$3.66K | 0.01% | 899 |
|
|
2015
Q1 | $522K | Buy |
17,049
+2,522
| +17% | +$98.1K | 0.01% | 1153 |
|
|
2014
Q4 | $739K | Buy |
+14,527
| New | +$650K | 0.01% | 1004 |
|
|
2014
Q3 | – | Sell |
-5,036
| Closed | -$217K | – | 2313 |
|
|
2014
Q2 | $217K | Buy |
+5,036
| New | +$192K | ﹤0.01% | 2120 |
|
Other funds holding ENTA
AC
FCM
B
KAM
ProShare Advisors's ENTA Position: Q1 2023 in Review
ProShare Advisors sold out of Enanta Pharmaceuticals (ENTA) in Q1 2023, closing a stake of 4,808 shares — an estimated $224K sold.
ProShare Advisors first reported a position in ENTA in Q2 2014 and held it in 34 quarters. The position peaked at $1.25M in Q2 2018. 144 funds tracked by Wall St. Rank hold ENTA as of Q1 2023.
- ProShare Advisors reported no remaining Enanta Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
- ProShare Advisors sold 4,808 Enanta Pharmaceuticals shares in Q1 2023, an estimated $224K.
- ProShare Advisors first reported a position in Enanta Pharmaceuticals in Q2 2014 and held it in 34 quarters.
- ProShare Advisors's Enanta Pharmaceuticals position peaked at $1.25M in Q2 2018.
- 144 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2023.
Based on ProShare Advisors's 13F filing for Q1 2023, filed 12 May 2023.